COVID-19 Small Molecule Therapeutics for PrEP
BARDA requested project proposals from product developers for the advanced clinical development and assessment of Next-Generation Therapeutics for COVID-19. BARDA has previously identified a capability gap for therapeutics that provide protection through Pre-exposure Prophylaxis (PrEP) and treatment against new SARS-CoV-2 variants. The purpose of this project is to partner with developers and other organizations to advance the clinical development of Next-Generation Therapeutics for COVID-19. The goal of this project is to provide better COVID-19 solutions and bolster preparedness and response against future health security threats.
Award Details
Advanced Development of S-892216 Long Acting Injectable for PrEP of COVID-19
Project Details
Member Organization: Shionogi
Award Date: 01/15/2025
Award Amount: $375,529,647
Project Duration: 84 months
Solicitation Number: RRPV RPP-24-03-SmMol
Project Objective: The objective of this project is to advance the development of S-892216, a 3CL protease inhibitor, as a long-acting injectable for COVID-19 pre-exposure prophylaxis. This will address a gap in therapeutics that have the potential to provide protection against severe outcomes of COVID-19.
